Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T18:04:53.685Z.
Calculation as of: 2026-10-06T18:04:53.685Z.
Quote observation: 2026-10-06T17:58:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6423558485129ce458f63e69d797580679928a9eb272818a894d3cfd838ee462
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$4.94M
EV/FCF Ratio
N/A
TTM Avg
7.51x
3Y Avg
7.51x
5Y Avg
7.51x
Market Cap
$5.00M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.03M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PharmaCyte Biotech, Inc. (PMCB) | $4.71M | N/A | N/A | N/A | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.66M | N/A | N/A | N/A | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.88M | N/A | N/A | N/A | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.51M | N/A | N/A | N/A | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.92M | N/A | N/A | N/A | N/A |
| Xenetic Biosciences, Inc. (XBIO)vs › | $4.94M | N/A | 7.51x | 7.51x | 7.51x |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.00M | N/A | N/A | N/A | N/A |
| Imunon, Inc. (IMNN)vs › | $5.02M | N/A | 11.91x | 14.69x | 14.69x |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.03M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.34M | N/A | 57.42x | 57.42x | 57.42x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute